Related Experiment Video
Updated: Jun 10, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Immunosuppressants: what's new?
Dominic Dell-Olio1, Deirdre A Kelly
1Liver Unit, Birmingham Children's Hospital Foundation Trust, Birmingham, UK.
Current Opinion in Organ Transplantation
|July 24, 2010
Summary
Recent advances in pediatric liver transplantation focus on novel immunosuppression strategies. This includes induction agents, corticosteroid avoidance, and calcineurin inhibitor minimization to improve long-term outcomes and quality of life for young survivors.
Area of Science:
- Immunology
- Transplantation Science
- Pediatric Medicine
Background:
- Pediatric liver transplantation success has increased, leading to more adult survivors facing long-term complications.
- Improved understanding of immune responses drives new immunosuppression strategies.
- Focus is shifting towards improving quality of life and reducing drug toxicity in young transplant recipients.
Purpose of the Study:
- To review current trends and advances in immunosuppression for pediatric liver transplantation.
- To highlight developments over the past 12 months.
Main Methods:
- Review of recent literature on immunosuppressive protocols in pediatric liver transplantation.
- Focus on induction agents, corticosteroid avoidance, and calcineurin inhibitor minimization.
- Examination of emerging strategies for operational tolerance and improved quality of life.
Main Results:
- Induction immunosuppression with targeted biological agents is increasingly adopted.
- Corticosteroid avoidance and calcineurin inhibitor minimization show promising results.
- New drugs targeting B-cell and complement pathways are under development.
Conclusions:
- Current trends emphasize induction agents, corticosteroid avoidance, and calcineurin inhibitor sparing.
- Strategies are evolving to induce operational tolerance in pediatric liver transplant recipients.
- New therapeutic agents are being developed to enhance long-term outcomes and quality of life.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...